Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment

Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment

IntroductionSmall cell lung cancer (SCLC) transformation serves as a significant mechanism of resistance to tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. To address this clinical challenge, we conducted a retr...

Full description

Bibliographic Details
Main Authors: Yongxia Chen, Mengye He, Zhengfeng Dai, Yina Wang, Jing Chen, Xiaoting Wang, Xiao Dong, Jianfei Huang, Jian Ruan, Xiaochen Zhang, Peng Shen, Yunlu Jia
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Oncology
Subjects:
small cell lung cancer transformation
EGFR mutation
tyrosine kinase inhibitor
TP53
RB1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1308313/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1308313/full

Similar Items